Skip to main content
SpringerLink
Log in
Book cover

Diabetic Cardiomyopathy pp 313–321Cite as

The Next Generation of Diagnostic Biomarkers for Type 2 Diabetes

  • Chapter
  • First Online:

Part of the book series: Advances in Biochemistry in Health and Disease ((ABHD,volume 9))

Abstract

Diabetes is a major cause of morbidity and mortality in both the United States and Asia. The greatest public health impact of diabetes is its vascular complications, which include both microvascular (retinopathy, nephropathy, and neuropathy) and macrovascular (ischemic heart disease, cerebrovascular disease, peripheral vascular disease) processes. Given that the diabetes epidemic continues to grow worldwide, there is a clear need for improvements in the management of the disease and its complications. The identification of biomarkers and pathogenic determinants of progression not only could provide tools physicians could use to monitor disease progression but could also give important insights into the mechanisms behind diabetic vascular complications, thus potentially opening new avenues for treatment.

The roles played by circulating miRNAs in diabetes mellitus (DM) and its vascular complications, both as biomarkers of disease and as critical contributors to disease progression, are not very clear. Recently, researchers have identified powerful roles for circulating miRNAs and their potential therapeutic implications, partly by advances in various technologies with which researchers can identify circulating miRNAs (next-generation sequencing, RNA Seq, digital qPCR, etc.) and then successfully isolate and study them. Circulating miRNAs play a role in the metabolic, inflammatory, and antiangiogenic pathways in type 2 diabetes (T2D).

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Whiting DR, Guariguata L, Weil C, Shaw J (2011) IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 94:311–321

    Article  PubMed  Google Scholar 

  2. Saaddine JB, Honeycutt AA, Narayan KM et al (2008) Projection of diabetic retinopathy and other major eye diseases among people with diabetes mellitus: United States, 2005–2050. Arch Ophthalmol 126:1740–1747

    Article  PubMed  Google Scholar 

  3. Schernthaner G, Schernthaner GH (2013) Diabetic nephropathy: new approaches for improving glycemic control and reducing risk. J Nephrol. doi:10.5301/jn.5000281. [Epub ahead of print]

  4. Kumar PJ, Clark M (2002) Textbook of clinical medicine. Saunders, London

    Google Scholar 

  5. Mellitus ECotDaCoD (1997) Report of the expert committee on the diagnosis and classification of diabetes mellitus. Committee Reports & Consensus Statements. Diabetes Care 20:1183–1197

    Google Scholar 

  6. Beverley B, Eschwège E (2003) The diagnosis and classification of diabetes and impaired glucose tolerance. In: Textbook of Diabetes 1 Ed: John C Pickup and Gareth Williams Third edition; Chapter 2, pp 2.1-2.11.

    Google Scholar 

  7. Johnson JA, et al (2002) Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care 25:2244–2248

    Google Scholar 

  8. Amos AF, McCarty DJ, Zimmet P (1997) The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med 14(Suppl 5):S1–S85

    PubMed  Google Scholar 

  9. King H, Aubert RE, Herman WH (1998) Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care 21:1414–1431

    Article  CAS  PubMed  Google Scholar 

  10. Zimmet P (2000) Globalization, coca-colonization and the chronic disease epidemic: can the Doomsday scenario be averted? J Intern Med 247:301–310

    Article  CAS  PubMed  Google Scholar 

  11. Foong AW, Saw SM, Loo JL et al (2007) Rationale and methodology for a population-based study of eye diseases in Malay people: the Singapore Malay Eye Study (SiMES). Ophthalmic Epidemiol 14:25–35

    Article  PubMed  Google Scholar 

  12. Cheung N, Mitchell P, Wong TY (2010) Diabetic retinopathy. Lancet 376:124–136

    Article  PubMed  Google Scholar 

  13. Cheung N, Wang JJ, Klein R et al (2007) Diabetic retinopathy and the risk of coronary heart disease: the Atherosclerosis Risk in Communities Study. Diabetes Care 30:1742–1746

    Article  PubMed  Google Scholar 

  14. Cheung N, Rogers S, Couper DJ et al (2007) Is diabetic retinopathy an independent risk factor for ischemic stroke? Stroke 38:398–401

    Article  PubMed  Google Scholar 

  15. Bastaki S (2005) Diabetes mellitus and its treatment. Int J Diabetes Metab 13:111–134

    Google Scholar 

  16. McLarty DG, Athaide I, Bottazzo GF et al (1990) Islet cell antibodies are not specifically associated with insulin-dependent diabetes in Tanzanian Africans. Diabetes Res Clin Pract 9:219–224

    Article  CAS  PubMed  Google Scholar 

  17. Ahren B, Corrigan CB (1985) Intermittent need for insulin in a subgroup of diabetic patients in Tanzania. Diabet Med 2:262–264

    CAS  PubMed  Google Scholar 

  18. DeFronzo RA (1997) Pathogenesis of NIDDM. Wiley, Chichester

    Google Scholar 

  19. Group RoWHOS Report of a WHO Study Group (1994) Prevention of diabetes mellitus. In: World Health Organ Tech Rep Ser. 844:1–100

    Google Scholar 

  20. Harris MI, Flegal KM, Cowie CC et al (1998) Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988–1994. Diabetes Care 21:518–524

    Article  CAS  PubMed  Google Scholar 

  21. Zimmet P (1982) Type 2 (non-insulin-dependent) diabetes—an epidemiological overview. Diabetologia 22:399–411

    Article  CAS  PubMed  Google Scholar 

  22. Christacopoulos P (1975) The prevalence of diabetes mellitus and non-diabetic glycosuria in a rural population in Greece. Diabetologia 11:A-335

    Google Scholar 

  23. Bloomgarden ZT (1996) American Diabetes Association annual meeting 1996: the etiology of type II diabetes, obesity, and the treatment of type II diabetes. Diabetes Care 19:1311–1315

    CAS  PubMed  Google Scholar 

  24. Eriksson J, Saloranta C, Widen E et al (1991) Non-esterified fatty acids do not contribute to insulin resistance in persons at increased risk of developing type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 34:192–197

    Article  CAS  PubMed  Google Scholar 

  25. Glaser NS (1997) Non-insulin-dependent diabetes mellitus in childhood and adolescence. Pediatr Clin N Am 44:307–337

    Article  CAS  Google Scholar 

  26. Scott CR, Smith JM, Cradock MM, Pihoker C (1997) Characteristics of youth-onset noninsulin-dependent diabetes mellitus and insulin-dependent diabetes mellitus at diagnosis. Pediatrics 100:84–91

    Article  CAS  PubMed  Google Scholar 

  27. Cockram CS (2000) Diabetes mellitus: perspective from the Asia-Pacific region. Diabetes Res Clin Pract 50(Suppl 2):S3–S7

    Article  PubMed  Google Scholar 

  28. Papa G, Degano C, Iurato MP et al (2013) Macrovascular complication phenotypes in type 2 diabetic patients. Cardiovasc Diabetol 12:20

    Article  PubMed Central  PubMed  Google Scholar 

  29. Kannel WB, McGee DL (1979) Diabetes and cardiovascular disease. The Framingham Study. JAMA 241:2035–2038

    Article  CAS  PubMed  Google Scholar 

  30. Harris MI, Klein R, Welborn TA, Knuiman MW (1992) Onset of NIDDM occurs at least 4–7 yr before clinical diagnosis. Diabetes Care 15:815–819

    Article  CAS  PubMed  Google Scholar 

  31. Dolben J, Owens D, Young S, Vora J, Atiea J, Dean J, Luzio S (1988) Retinopathy at presentation in type 2 (non-insulin dependent) diabetic patients. Diabet Med 5(Suppl 2):20

    Google Scholar 

  32. Arcidiacono MV, Traveset A, Rubinat E et al (2013) Microangiopathy of large artery wall: a neglected complication of diabetes mellitus. Atherosclerosis 228:142–147

    Article  CAS  PubMed  Google Scholar 

  33. Meigs JB, Hu FB, Rifai N, Manson JE (2004) Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus. JAMA 291:1978–1986

    Article  CAS  PubMed  Google Scholar 

  34. Meigs JB (2009) Multiple biomarker prediction of type 2 diabetes. Diabetes Care 32:1346–1348

    Article  CAS  PubMed  Google Scholar 

  35. Roy MS, Janal MN, Crosby J, Donnelly R (2013) Inflammatory biomarkers and progression of diabetic retinopathy in African Americans with type 1 diabetes. Invest Ophthalmol Vis Sci 54:5471–5480

    Article  CAS  PubMed  Google Scholar 

  36. Yang MH, Wang HY, Lu CY et al (2013) Proteomic profiling for peritoneal dialysate: differential protein expression in diabetes mellitus. BioMed Res Int 2013:642964

    PubMed Central  PubMed  Google Scholar 

  37. Chu L, Fu G, Meng Q et al (2013) Identification of urinary biomarkers for type 2 diabetes using bead-based proteomic approach. Diabetes Res Clin Pract 101:187–193

    Article  CAS  PubMed  Google Scholar 

  38. Lu YC, Wang CP, Hsu CC et al (2013) Circulating secreted frizzled-related protein 5 and wingless-type MMTV integration site family member 5a levels in patients with type 2 diabetes mellitus. Diabetes Metab Res Rev 29:551–556

    Google Scholar 

  39. Gradinaru D, Borsa C, Ionescu C, Margina D (2013) Advanced oxidative and glycoxidative protein damage markers in the elderly with type 2 diabetes. J Proteomics 92:313–322

    Google Scholar 

  40. Cheung CL, Lam KS, Cheung BM (2013) Serum beta-2 microglobulin predicts mortality in people with diabetes. Eur J Endocrinol 169:1–7

    Article  CAS  PubMed  Google Scholar 

  41. Zhao ZW, Lin CG, Wu LZ et al (2013) Serum fetuin-A levels are associated with the presence and severity of coronary artery disease in patients with type 2 diabetes. Biomarkers 18:160–164

    Article  CAS  PubMed  Google Scholar 

  42. Muni RH, Kohly RP, Lee EQ et al (2013) Prospective study of inflammatory biomarkers and risk of diabetic retinopathy in the diabetes control and complications trial. JAMA Ophthalmol 131:514–521

    Article  CAS  PubMed  Google Scholar 

  43. Das S, Ferlito M, Kent OA et al (2012) Nuclear miRNA regulates the mitochondrial genome in the heart. Circ Res 110:1596–1603

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  44. Arroyo JD, Chevillet JR, Kroh EM et al (2011) Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci U S A 108:5003–5008

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  45. Vickers KC, Palmisano BT, Shoucri BM et al (2011) MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol 13:423–433

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  46. Wang K, Zhang S, Weber J et al (2010) Export of microRNAs and microRNA-protective protein by mammalian cells. Nucleic Acids Res 38:7248–7259

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  47. Hunter MP, Ismail N, Zhang X et al (2008) Detection of microRNA expression in human peripheral blood microvesicles. PLoS One 3:e3694

    Article  PubMed Central  PubMed  Google Scholar 

  48. Kato M, Zhang J, Wang M et al (2007) MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibition of E-box repressors. Proc Natl Acad Sci U S A 104:3432–3437

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  49. Kato M, Wang L, Putta S et al (2010) Post-transcriptional up-regulation of Tsc-22 by Ybx1, a target of miR-216a, mediates TGF-beta-induced collagen expression in kidney cells. J Biol Chem 285:34004–34015

    Article  CAS  PubMed  Google Scholar 

  50. Deshpande SD, Putta S, Wang M et al (2013) Transforming growth factor-beta induced cross talk between p53 and a microRNA in the pathogenesis of diabetic nephropathy. Diabetes 62:3151–3162

    Article  CAS  PubMed  Google Scholar 

  51. Kovacs B, Lumayag S, Cowan C, Xu S (2011) MicroRNAs in early diabetic retinopathy in streptozotocin-induced diabetic rats. Invest Ophthalmol Vis Sci 52:4402–4409

    Article  CAS  PubMed  Google Scholar 

  52. Feng B, Chen S, McArthur K et al (2011) miR-146a-mediated extracellular matrix protein production in chronic diabetes complications. Diabetes 60:2975–2984

    Article  CAS  PubMed  Google Scholar 

  53. McArthur K, Feng B, Wu Y et al (2011) MicroRNA-200b regulates vascular endothelial growth factor-mediated alterations in diabetic retinopathy. Diabetes 60:1314–1323

    Article  CAS  PubMed  Google Scholar 

  54. Feng B, Chen S, George B et al (2010) miR133a regulates cardiomyocyte hypertrophy in diabetes. Diabetes Metab Res Rev 26:40–49

    Article  CAS  PubMed  Google Scholar 

  55. Shen E, Diao X, Wang X et al (2011) MicroRNAs involved in the mitogen-activated protein kinase cascades pathway during glucose-induced cardiomyocyte hypertrophy. Am J Pathol 179:639–650

    Article  CAS  PubMed  Google Scholar 

  56. Greco S, Fasanaro P, Castelvecchio S et al (2012) MicroRNA dysregulation in diabetic ischemic heart failure patients. Diabetes 61:1633–1641

    Article  CAS  PubMed  Google Scholar 

  57. Mitchell PS, Parkin RK, Kroh EM et al (2008) Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 105:10513–10518

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  58. Wang GK, Zhu JQ, Zhang JT, Li Q, Li Y, He J, Qin YW, Jing Q (2010) Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur Heart J 31:659–666

    Article  PubMed  Google Scholar 

  59. Ji X, Takahashi R, Hiura Y, Hirokawa G, Fukushima Y, Iwai N (2009) Plasma miR-208 as a biomarker of myocardial injury. Clin Chem 55:1944–1949

    Article  CAS  PubMed  Google Scholar 

  60. Fichtlscherer S, De Rosa S, Fox H, Schwietz T, Fischer A, Liebetrau C, Weber M, Hamm CW, Röxe T, Müller-Ardogan M, Bonauer A, Zeiher AM, Dimmeler S (2010) Circulating microRNAs in patients with coronary artery disease. Circ Res 107:677–684

    Article  CAS  PubMed  Google Scholar 

  61. Tijsen AJ, Creemers EE, Moerland PD, de Windt LJ, van der Wal AC, Kok WE, Pinto YM (2010) MiR423-5p as a circulating biomarker for heart failure. Circ Res 106:1035–1039

    Article  CAS  PubMed  Google Scholar 

  62. Sebastiani G, Grieco FA, Spagnuolo I et al (2011) Increased expression of microRNA miR-326 in type 1 diabetic patients with ongoing islet autoimmunity. Diabetes Metab Res Rev 27: 862–866

    Article  CAS  PubMed  Google Scholar 

  63. Zampetaki A, Kiechl S, Drozdov I et al (2010) Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ Res 107:810–817

    Article  CAS  PubMed  Google Scholar 

  64. Balasubramanyam M, Aravind S, Gokulakrishnan K et al (2011) Impaired miR-146a expression links subclinical inflammation and insulin resistance in Type 2 diabetes. Mol Cell Biochem 351:197–205

    Article  CAS  PubMed  Google Scholar 

  65. Chavali V, Tyagi SC, Mishra PK (2012) MicroRNA-133a regulates DNA methylation in diabetic cardiomyocytes. Biochem Biophys Res Commun 425:668–672

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiac-Pathology, Johns Hopkins University, Baltimore, MD, USA

    Samarjit Das Ph.D.

  2. Department of Pathology, Cardiac Division, Johns Hopkins University, Baltimore, MD, 21205, USA

    Samarjit Das Ph.D.

  3. University of Malaya Eye Research Centre Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia

    Tengku Ain Kamalden D. Phil

Authors
  1. Samarjit Das Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tengku Ain Kamalden D. Phil
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Samarjit Das Ph.D. .

Editor information

Editors and Affiliations

  1. Department of Biophysics, University of Ankara, Ankara, Ankara, Turkey

    Belma Turan

  2. St. Boniface Hosp. Research, Univ. of Ma Institute of Cardiovascular Sciences, Winnipeg, Manitoba, Canada

    Naranjan S. Dhalla

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media New York

About this chapter

Cite this chapter

Das, S., Kamalden, T.A. (2014). The Next Generation of Diagnostic Biomarkers for Type 2 Diabetes. In: Turan, B., Dhalla, N. (eds) Diabetic Cardiomyopathy. Advances in Biochemistry in Health and Disease, vol 9. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-9317-4_19

Download citation

Publish with us

Policies and ethics

Search

Navigation